Innophos highlights new clinical research that demonstrates Oxyjun® Terminalia Arjuna Extract helps promote cardiac output and reduces physical fatigue*
Innophos, a leading international producer of nutritional specialty ingredients and custom formulated solutions, today announced the release of new clinical findings from ENovate Biolife highlighting Oxyjun®, a premium branded extract of Terminalia arjuna. Extracted from the bark of the Arjuna tree, Terminalia arjuna has traditionally been used for cardio protection purposes. The findings from this latest human clinical trial demonstrate advanced benefits in the areas of cardiac output and perceived reduction in physical fatigue in study subjects.
“Cardiac health is of the utmost importance for today’s consumers, and we are excited about the beneficial findings of Oxyjun® from this study,” said Dr. Bruce Abedon, R&D Senior Manager at Innophos and co-author of the study. “As the exclusive licensed distributor of Oxyjun® in North America, our team at Innophos is committed to providing the highest quality, science-backed products, and continuing our partnership with ENovate Biolife.”